L-arginine as an antihypertensive agent.

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Nephrology

Background:

• Hypertension is a significant cardiovascular risk factor.
• Nitric oxide (NO) plays a crucial role in regulating vascular tone.
• Endogenous NO production may be impaired in hypertensive states.

Purpose of the Study:

• To investigate the effects of intravenous L-arginine administration in patients with various forms of hypertension.
• To assess whether exogenous L-arginine can stimulate nitric oxide (NO) release in vivo.
• To evaluate the impact of L-arginine on hemodynamic parameters in hypertensive individuals.

Main Methods:

• Intravenous administration of L-arginine to patients with essential hypertension, renovascular hypertension, primary aldosteronism, and Cushing's syndrome.
• Monitoring of hemodynamic parameters including mean arterial pressure, cardiac output, and total peripheral resistance.
• Measurement of biomarkers for NO release, such as plasma L-citrulline and urinary nitrite/nitrate.

Main Results:

• L-Arginine administration led to a decrease in mean arterial pressure across all patient groups.
• Cardiac output increased, while total peripheral resistance decreased during L-arginine infusion.
• Plasma L-citrulline levels and urinary nitrite/nitrate excretion increased, indicating enhanced NO release.

Conclusions:

• Exogenous L-arginine effectively reduces blood pressure in hypertensive patients.
• L-Arginine stimulates nitric oxide (NO) production in vivo, contributing to vasodilation.
• L-arginine represents a potential therapeutic strategy for managing hypertension through NO enhancement.